Louis Garguilo's Articles
-
Small Molecules And The Arc Of Time
5/15/2023
“I've been trained, and doing the same stuff since I was 25. The same experiments for 50 some years, a long time. I guess you could call what I am describing as the arc of time for small molecules,” says Kintara Therapeutics cofounder and CSO Dennis Brown.
-
Large Balloons Over America, Small Molecules In China
5/8/2023
Coinciding with U.S. and China relations continuing to deflate, but with no premeditated intention, my discussion with President and CEO of Kintara Therapeutics, Robert E. Hoffman, and CSO Dennis Brown, focused on the role of China-based CDMOs.
-
Is Technology The New Science Of Outsourcing?
5/4/2023
That’s the abstruse thought with which I left the 2023 CDMO Leadership Awards ceremony in Manhattan. I’ve subsequently tried to sort this out by referring back to a series of interviews I did with CDMO leaders at the event. I think now I can explain this to readers.
-
May I Present, The Consultant
5/1/2023
We’ve been investigating the importance of consultants for outsourcing assistance. It’s time to get personal. How much value-addition and experience can one individual bring to your outsourcing operations, and your odds of success?Allow me to present exhibit one: Antkisha Joshi.
-
Your Consultants, Your Destiny
4/24/2023
Chief Editor Louis Garguilo has been doggedly pursuing this hypothesis with biopharma professionals: Consultants have become more important than ever. His resulting correspondences shed light on the role of consultants, and also on where we are as a development and manufacturing outsourcing community.
-
Create A Quality-System Plan Before Outsourcing
4/20/2023
A first piece of advice for those companies outsourcing to CDMOs: Create and have firmly in place your own quality-system plan. And it doesn't matter if you're a virtual company, says Antiksha Joshi, a quality management systems professional. Do this before approaching those potential partners.
-
Check The Rolodex: China For Steroids, Europe For Biologics
4/17/2023
Part 2 of our discussion with Philadelphia-based Context Therapeutics CEO Martin Lehr, in which he shares his Rolodex and some intriguing outsourcing advice for both biologics and small molecules, both a part of his pipeline.
-
Small Or Large Molecule: Unifying Essentials For Development
4/10/2023
One startup. Two assets – the first a small molecule (SM); the second a biologic. Both assets are being developed via a fully outsourced strategy – the first is in China; the other Europe. It adds up to an informative discussion on outsourcing with Context Therapeutics CEO, Martin Lehr.
-
ChatGPT Wrote This Editorial
4/6/2023
How could I resist? I just had to direct ChatGPT to do this: “Please write an editorial on drug development and manufacturing outsourcing in the style of Louis Garguilo, Chief Editor of Outsourced Pharma (OutsourcedPharma.com).” Here's what I got back.
-
CDMOs And Hospitals Pursue Cures For Rare Disease
4/3/2023
A child is diagnosed with an ultra-rare disease. No biotech or pharma is interested in developing a gene therapy for the condition. In this final of our 3-part narrative, we learn how and where the INADcure Foundation found some help.